Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer
暂无分享,去创建一个
F. Gao | R. Govindan | B. Meyers | B. Siegel | B. Goodgame | F. Dehdashti | A. Patterson | F. Gao | J. Shriki | G. Pillot | Zhi-yun Yang | J. Zoole
[1] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[2] Rakesh Kumar,et al. Positron emission tomography: clinical applications in oncology. Part 1 , 2005, Expert review of anticancer therapy.
[3] R. Wahl,et al. Does the FDG Uptake of Primary Non-Small Cell Lung Cancer Predict Prognosis?. A Work in Progress. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[4] Julio Astudillo,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.
[5] C. Mountain,et al. Revisions in the International System for Staging Lung Cancer. , 1997, Chest.
[6] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[7] B. Franc,et al. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma. , 2006, The Journal of thoracic and cardiovascular surgery.
[8] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[9] H. Groen,et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.
[10] J. Soria,et al. Adjuvant chemotherapy in early-stage non-small cell lung cancer. , 2005, Seminars in oncology.
[11] R. Govindan,et al. Prognostic Value of Fluorodeoxyglucose Positron Emission Tomography in Non-small Cell Lung Cancer: A Review , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] Robert Livingston,et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.
[13] R. Cerfolio,et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.
[14] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Yukiko Arisaka,et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] M. Boers,et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.
[17] G. V. von Schulthess,et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.
[18] D. Sugarbaker,et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Naruke,et al. Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.
[20] T. Naruke,et al. Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.